O-(2-chloro-6-fluorobenzyl)hydroxylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-(2-chloro-6-fluorobenzyl)hydroxylamine
• 英文别名: O-[(2-chloro-6-fluorophenyl)methyl]hydroxylamine
• 化学式: C₇H₇ClFNO
• 分子量: 175.59
• InChiKey: LROSJIONKOYASE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-(2-chloro-6-fluorobenzyl)hydroxylamine 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 72.0h， 生成 O-[(2-氯-6-氟苯基)甲基]羟胺盐酸盐
  参考文献：
  名称：

  Synthesis and Fungicidal Activity of Macrolactams and Macrolactones with an Oxime Ether Side Chain

  摘要：

  Three series of novel macrolactams and macrolactones - 12-alkoxyimino-tetradecanlactam, 12-alkoxyiminopentadecanlactam, and 12-alkoxyiminodecanlactone derivatives (7A, 7B, and 7C) - were synthesized from corresponding 12-oxomacrolactams and 12-oxomacrolactone. Their structures were confirmed by H-1 NMR and elemental analysis. The Z and E isomers of 7A and 7B were separated, and their configurations were determined by H-1 NMR. These compounds showed fair to excellent fungicidal activities against Rhizoctonia solani Kuhn. It is interesting that the Z and E isomers of most of the compounds have quite different fungicidal activities. The fact that the compounds have a gradual increase of fungicidal activity in the order of 7A, 7C, and 7B indicated that the macrocyclic derivatives with a hydrogen-bonding acceptor (=N-O-) and a hydrogen-bonding donor (-CONH-) on the ring, and a three methylenes distance (CH2CH2CH2) between these two functional groups, exhibited the best fungicidal activity. The bioassay also showed that 7B not only has good fungicidal activity but also may have a broad spectrum of fungicidal activities.

  DOI：

  10.1021/jf072733+
• 作为产物：
  描述：

  2-[(2-Chloro-6-fluorophenyl)methoxy]isoindole-1,3-dione 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 O-(2-chloro-6-fluorobenzyl)hydroxylamine
  参考文献：
  名称：

  Synthesis and Fungicidal Activity of Macrolactams and Macrolactones with an Oxime Ether Side Chain

  摘要：

  Three series of novel macrolactams and macrolactones - 12-alkoxyimino-tetradecanlactam, 12-alkoxyiminopentadecanlactam, and 12-alkoxyiminodecanlactone derivatives (7A, 7B, and 7C) - were synthesized from corresponding 12-oxomacrolactams and 12-oxomacrolactone. Their structures were confirmed by H-1 NMR and elemental analysis. The Z and E isomers of 7A and 7B were separated, and their configurations were determined by H-1 NMR. These compounds showed fair to excellent fungicidal activities against Rhizoctonia solani Kuhn. It is interesting that the Z and E isomers of most of the compounds have quite different fungicidal activities. The fact that the compounds have a gradual increase of fungicidal activity in the order of 7A, 7C, and 7B indicated that the macrocyclic derivatives with a hydrogen-bonding acceptor (=N-O-) and a hydrogen-bonding donor (-CONH-) on the ring, and a three methylenes distance (CH2CH2CH2) between these two functional groups, exhibited the best fungicidal activity. The bioassay also showed that 7B not only has good fungicidal activity but also may have a broad spectrum of fungicidal activities.

  DOI：

  10.1021/jf072733+

文献信息

• Synthesis of anthelmintically activeN-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A
  作者：Peter Jeschke、Achim Harder、Georg von Samson-Himmelstjerna、Winfried Etzel、Wolfgang Gau、Gerhard Thielking、Gerhard Bonse

  DOI：10.1002/ps.590

  日期：2002.12

  product PF1022A. In particular an improved efficacy against Haemonchus contortus Rudolphi and Trichostrongylus colubriformis Giles in sheep compared to the potent cyclic octadepsipeptide PF1022A and its mono-thionated derivative has been observed. Here we report on a specific modification at the N-methyl amide linkage by using the mono-thionated PF1022A, resulting in novel anthelmintically active backbone

  环状十八肽PF1022A的N-甲基化a胺肟类似物代表新型衍生物，具有体外抗旋毛虫欧文和巴西柔毛夜蛾活性，并具有抗小鼠和绵羊寄生线虫的活性。与天然产物PF1022A相比，它们中的一些在小鼠中表现出更好的抗Hymenolepis nana Siebold，Spterosa Schneider和Heligmosomoides polygyrus Dujardin活性。尤其是，与强效的环八肽肽PF1022A及其单亚硫代衍生物相比，已观察到对绵羊的弯曲变形金丝猴（Ruemonphi Rutorphi）和毛细线虫（Trichostrongylus colubriformis Giles）有改善的功效。在这里，我们报告了通过使用单亚硫代PF1022A在N-甲基酰胺键处的特定修饰，从而产生了PF 1022A的新型具有抗炎活性的骨架类似物。
• [EN] PRODRUG INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1)<br/>[FR] INHIBITEURS DE PROMÉDICAMENTS D'INDOLÉAMINE 2,3-DIOXYGÉNASE-1 (JDO1)
  申请人：LANKENAU INST MEDICAL RES

  公开号：WO2019051198A1

  公开（公告）日：2019-03-14

  Indoleamine 2,3-dioxygenase-1 prodrugs and methods of use thereof are disclosed.

  揭示了吲哚胺2,3-二氧化酶-1前药及其使用方法。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• NODULISPORIC ACID DERIVATIVES
  申请人：Merck & Co., Inc.

  公开号：EP0819000B1

  公开（公告）日：2009-07-08
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15